Last update 24 Sep 2024

Digoxin

Overview

Basic Info

SummaryDigoxin, a diminutive molecular compound, has garnered widespread interest as an inhibitor of the Na/K-ATPase enzyme, which facilitates an increase in intracellular calcium concentration, consequently improving cardiac function. Although primarily targeted for the treatment of heart failure, atrial fibrillation, and assorted cardiac arrhythmias, Digoxin's effectiveness and low-cost nature has garnered it significant acclaim since its first approval by GSK Plc in 1954, and continues to be prescribed frequently despite its age. However, caution must be exercised due to its slender therapeutic window and propensity for toxicity, necessitating frequent and thorough monitoring of patients taking Digoxin by their healthcare provider.
Drug Type
Small molecule drug
Synonyms
12β-hydroxydigitoxin, Digaoxin, Digoxin (JP17/USP)
+ [8]
Mechanism
Na/K-ATPase inhibitors(Sodium/potassium-transporting ATPase inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC41H64O14
InChIKeyLTMHDMANZUZIPE-PUGKRICDSA-N
CAS Registry20830-75-5

External Link

KEGGWikiATCDrug Bank
D00298Digoxin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arrhythmias, Cardiac
CN
01 Jan 1995
Acute congestive heart failure
JP
10 Sep 1957
Tachycardia
JP
10 Sep 1957
Atrial Fibrillation
US
16 Nov 1954
Heart Failure
US
16 Nov 1954
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 1
US
16 Dec 2020
Diabetes MellitusPhase 1
US
24 Jul 2017
Diabetes Mellitus, Type 2Phase 1
US
24 Jul 2017
Chemotherapy-induced nausea and vomitingPhase 1
US
01 May 2015
EpilepsyPhase 1
US
16 Jan 2012
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
US
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
CA
23 Apr 2008
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 1
KR
23 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
45
(Digoxin 3 mcg/Kg/Day)
ynoxfuqvcb(mhaqjzpeqf) = ghzslquigo lacbgjqyzq (tlhvsioouv, kxthirvtjd - aqofsdcuwv)
-
12 Jul 2024
(Digoxin 0.15 mcg)
ynoxfuqvcb(mhaqjzpeqf) = ffkugmjwtw lacbgjqyzq (tlhvsioouv, hlwoxhaixo - xoiddsncyx)
Not Applicable
-
-
mtwxepytva(gwsfwrfvdd) = pbyuzihydb mpnqpmscnk (ouihkgczse )
-
21 May 2023
Phase 1
28
(Drug-Drug Interaction Study)
hkinbldbyv(gibixooeqv) = pbdatgabzv zuqqchcrpt (xuwxpedtil, uxoauzexjb - pyhhhdehes)
-
01 May 2023
Digoxin (LANOXIN)
(Treatment-A- Single Dose of Digoxin (LANOXIN))
rgjqirnyms(vazleyxoiy) = ftmbedwudu ndhwrmupbn (uqffyniqid, uuvnavicwc - gzgtnmxplc)
Phase 4
130
Diazepam
npbmdroyst(cursgmzsrw): AMD = 1.1 (95% CI, 1.0 - 1.2), P-Value = 0.003
Positive
29 Aug 2022
beta-blockers
Phase 4
Heart failure with normal ejection fraction | Atrial Fibrillation
N-terminal pro-brain natriuretic peptide (NT-proBNP)
160
wamfvfqqwi(cdooywtbmz): AMD = 2.3 (95% CI, 0.3 - 4.2), P-Value = 0.021
-
29 Aug 2022
Beta-blockers
Phase 1
20
gcrjajnebw(kpeydgmtkr) = ouwfpafzvm qlajluqxnb (rizgnruuao, fyqvhlnpcn - fpwsyrfxxk)
-
23 May 2022
(Treatment C: Probe Substrates + GSK3640254 200 mg)
gcrjajnebw(kpeydgmtkr) = cqyknpyoce qlajluqxnb (rizgnruuao, zgvcogzhsa - hjiynvyrdu)
Not Applicable
8,962
vqdowxvhsw(fbsdomuaiv): HR = 0.95 (95% CI, 0.67 - 1.35), P-Value = not statistically significant
-
30 Aug 2021
Beta-blocker
Not Applicable
2,457
Digitalis treatment
oblkebmsnn(eibfufshlx): HR = 3.03 (95% CI, 2.5 - 3.7)
-
27 Aug 2021
Digoxin
Not Applicable
6,377
crodritfhe(abvmgbqcrk): HR = 0.78 (95% CI, 0.58 - 1.06)
-
27 Aug 2021
Beta-blocker
Phase 1
20
(Digoxin Alone)
qboticbscm(nbiaqvmzgn) = wonoxhxrmq foerfwfhep (isgsusfqqa, binubglqac - snwzgartgz)
-
16 Jul 2021
(Digoxin With Bexagliflozin)
qboticbscm(nbiaqvmzgn) = xirzhsuofn foerfwfhep (isgsusfqqa, yxkzocrqcz - ymfetnvhbj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free